Skip to main content

Patient Satisfaction

0
Pipeline Programs
7
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
1 program
Budesonide, Formoterol Fumarate DihydrateN/A1 trial
Active Trials
NCT02384577Completed4,034Est. Sep 2016
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
DPBRN Patient Satisfaction With Dental RestorationsN/A1 trial
Active Trials
NCT01201421Completed5,932Est. Mar 2010
GSK
GSKLONDON, United Kingdom
1 program
Switch From Oral Therapy to Long-acting Injectable Cabotegravir + RilpivirineN/A1 trial
Active Trials
NCT05835635Not Yet Recruiting50Est. May 2026
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
Switch From Oral Therapy to Long-acting Injectable Cabotegravir + RilpivirineN/A
Hyperfine
HyperfineCT - Guilford
1 program
Swoop Plus Mk2.0N/A1 trial
Active Trials
NCT06930534Recruiting300Est. Apr 2026
EvoEndo
EvoEndoCO - Centennial
1 program
Virtual Reality Distraction and DisassociationN/A1 trial
Active Trials
NCT06636292Completed30Est. Oct 2024
Innovation Pharmaceuticals
1 program
virtual phone appointment visitsN/A1 trial
Active Trials
NCT05998148Completed90Est. Jan 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKSwitch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine
HyperfineSwoop Plus Mk2.0
EvoEndoVirtual Reality Distraction and Disassociation
Innovation Pharmaceuticalsvirtual phone appointment visits
TevaBudesonide, Formoterol Fumarate Dihydrate
Oregon TherapeuticsDPBRN Patient Satisfaction With Dental Restorations

Clinical Trials (6)

Total enrollment: 10,436 patients across 6 trials

NCT05835635GSKSwitch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine

Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine

Start: May 2025Est. completion: May 202650 patients
N/ANot Yet Recruiting
NCT06930534HyperfineSwoop Plus Mk2.0

Portable Rapid Imaging for Medical Emergencies

Start: Apr 2025Est. completion: Apr 2026300 patients
N/ARecruiting
NCT06636292EvoEndoVirtual Reality Distraction and Disassociation

VRDD in Upper Gastrointestinal Endoscopy

Start: Feb 2024Est. completion: Oct 202430 patients
N/ACompleted
NCT05998148Innovation Pharmaceuticalsvirtual phone appointment visits

Virtual Phone Visits Compared to In-Person Physical Visits for Post-Operative Follow-Up at a Sports Medicine Clinic

Start: Mar 2022Est. completion: Jan 202490 patients
N/ACompleted
NCT02384577TevaBudesonide, Formoterol Fumarate Dihydrate

Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment

Start: Jul 2014Est. completion: Sep 20164,034 patients
N/ACompleted
NCT01201421Oregon TherapeuticsDPBRN Patient Satisfaction With Dental Restorations

DPBRN Patient Satisfaction With Dental Restorations

Start: Nov 2008Est. completion: Mar 20105,932 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 10,436 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.